Michael D. West, Ph.D.

Michael West has served as Chief Executive Officer of ReCyte Therapeutics, Inc. since its founding in January 2011.  He is a pioneer in the field of stem cell research and has extensive academic and business experience in age-related degenerative diseases, telomerase molecular biology and human embryonic stem cell research and development.  Prior to joining BioTime, Dr. West served as President and Chief Scientific Officer of Advanced Cell Technology, Inc, a company engaged in developing human stem cell technology for use in regenerative medicine.  Dr. West also founded Geron Corporation where he initiated and managed programs in telomerase diagnostics, oligonucleotide-based telomerase inhibition as anti-tumor therapy, and the cloning and use of telomerase in telomerase-mediated therapy wherein telomerase is utilized to immortalize human cells, and he initiated and managed the original collaborative effort that led to the first isolation of human embryonic stem and embryonic germ cells. Dr. West is a named inventor named on over 60 patents and patent applications in the field of biotechnology and also serves as an Adjunct Professor of Bioengineering at the University of California, Berkeley.  He has served on the BioTime Board of Directors since 2002. Dr. West received a B.S. Degree from Rensselaer Polytechnic Institute in 1976, an M.S. Degree in Biology from Andrews University in 1982, and a Ph.D. from Baylor College of Medicine in 1989 concentrating on the biology of cellular aging.


David Larocca joined ReCyte Therapeutics, Inc. as Vice President of Research and Development in September 2013. He previously founded Mandala Biosciences, LLC, where he served as Chief Executive Officer. At Mandala, he was Principal Investigator on several SBIR and CIRM awards aimed at improving therapeutic stem cell purity. Prior to Mandala, Dr. Larocca held positions at the Sanford Burnham Medical Research Institute, Advanced Cell Technology, Inc. and Selective Genetics, Inc. He is an inventor on 15 patents in the fields of immunotherapy, targeted gene therapy and regenerative medicine. Dr. Larocca holds a Ph.D. in Molecular and Cellular Biology from the University of Southern California and a B.S. in Biology from Ithaca College. He did his post-doctoral training at Harvard University.